J Pain Res:不同剂型及不同添加剂的局麻药效果

2017-05-30 MedSci MedSci原创

局部麻醉用于控制与许多程序相关的疼痛。现在最常用的局部麻醉是德国的EMLA(利多卡因/丙胺卡因)。然而,丙胺卡因是一种高铁血红蛋白诱导剂,使用具有局限性,尤其是在新生儿和婴儿中。本研究旨在评估丙胺卡因和利多卡因以及丙二醇(渗透促进剂)和氨丁三醇(缓冲物质)在麻醉剂中的应用效果。研究共纳入了29名健康成人,暴露于标准化疼痛刺激(钝/锋利0.2,0.4或0.8 N的压力)时,使用视觉模拟评分评估受试者

局部麻醉用于控制与许多程序相关的疼痛。现在最常用的局部麻醉是德国的EMLA(利多卡因/丙胺卡因)。然而,丙胺卡因是一种高铁血红蛋白诱导剂,使用具有局限性,尤其是在新生儿和婴儿中。本研究旨在评估丙胺卡因和利多卡因以及丙二醇(渗透促进剂)和氨丁三醇(缓冲物质)在麻醉剂中的应用效果。

研究共纳入了29名健康成人,暴露于标准化疼痛刺激(钝/锋利0.2,0.4或0.8 N的压力)时,使用视觉模拟评分评估受试者的实验疼痛,麻醉霜剂的暴露时间为20、40 或 60分钟。

结果只有在60分钟的曝光时间和0.8 N的压力时发现明显的结果,在20%的浓度下,与安慰剂相比,利多卡因更有效,与利多卡因/丙胺卡因同样有效。含10%利多卡因和额外的氨基丁三醇麻醉霜剂镇痛效果明显优于安慰剂组,不劣于利多卡因/丙胺卡因。在这项研究中,渗透促进剂丙二醇没有加速起效镇痛效果。相比之下,氨基丁三醇(Tris/THAM)的额外使用可加速起效(0.4和0.8 N)。在所有的成年受试者中,局部麻醉药膏测试的最低暴露时间为60分钟。

总而言之,这项研究的结果表明,含20%利多卡因、38%氨丁三醇、10%丙二醇的麻醉霜可作为与复方利多卡因相媲美的麻醉药物,且不需要延长暴露时间。

原始出处:

Christian Weilbach, Christian Hoppe, et al., Effectiveness of various formulations of local anesthetics and additives for topical anesthesia – a prospective, randomized, double-blind, placebo-controlled study. J Pain Res. 2017; 10: 1105–1109. Published online 2017 May 10. doi:  10.2147/JPR.S131029.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672299, encodeId=a12616e22990f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue May 01 14:33:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663852, encodeId=78be16638520a, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Sat Jan 13 07:33:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613776, encodeId=106b1613e76b6, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Thu Jun 01 07:33:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204712, encodeId=7594204e12c7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 31 08:10:05 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204471, encodeId=79472044e124, content=复方制剂的疗效对比, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue May 30 20:00:04 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2018-05-01 lsndxfj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672299, encodeId=a12616e22990f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue May 01 14:33:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663852, encodeId=78be16638520a, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Sat Jan 13 07:33:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613776, encodeId=106b1613e76b6, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Thu Jun 01 07:33:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204712, encodeId=7594204e12c7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 31 08:10:05 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204471, encodeId=79472044e124, content=复方制剂的疗效对比, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue May 30 20:00:04 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672299, encodeId=a12616e22990f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue May 01 14:33:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663852, encodeId=78be16638520a, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Sat Jan 13 07:33:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613776, encodeId=106b1613e76b6, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Thu Jun 01 07:33:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204712, encodeId=7594204e12c7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 31 08:10:05 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204471, encodeId=79472044e124, content=复方制剂的疗效对比, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue May 30 20:00:04 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672299, encodeId=a12616e22990f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue May 01 14:33:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663852, encodeId=78be16638520a, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Sat Jan 13 07:33:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613776, encodeId=106b1613e76b6, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Thu Jun 01 07:33:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204712, encodeId=7594204e12c7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 31 08:10:05 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204471, encodeId=79472044e124, content=复方制剂的疗效对比, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue May 30 20:00:04 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2017-05-31 130****4638

    学习了谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1672299, encodeId=a12616e22990f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue May 01 14:33:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663852, encodeId=78be16638520a, content=<a href='/topic/show?id=f6304e66252' target=_blank style='color:#2F92EE;'>#局麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47662, encryptionId=f6304e66252, topicName=局麻)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48cb25693766, createdName=12498b08m98暂无昵称, createdTime=Sat Jan 13 07:33:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613776, encodeId=106b1613e76b6, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Thu Jun 01 07:33:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204712, encodeId=7594204e12c7, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 31 08:10:05 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204471, encodeId=79472044e124, content=复方制剂的疗效对比, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue May 30 20:00:04 CST 2017, time=2017-05-30, status=1, ipAttribution=)]
    2017-05-30 cqykthl

    复方制剂的疗效对比

    0